Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04165031 · OUTCOME

Phase 1: PK: Average Concentration at Steady State of LY3499446 in Combination With Cetuximab

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation · Source last updated 2021-11-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Predose Cycle 1 Day 1 through Cycle 3 Day 1 (21 Day Cycles)

What was measured

PK: Average Concentration at Steady State of LY3499446 in Combination with Cetuximab

Analysis population: Zero participants were analyzed due to early termination of study.

Groups in this outcome

LY3499446 and Cetuximab Phase 1

LY3499446 in combination with cetuximab intravenously (IV).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
LY3499446 and Cetuximab Phase 10

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
PK: Average Concentration at Steady State of LY3499446 in Combination with Cetuximab
groups
  1. description
    LY3499446 in combination with cetuximab intravenously (IV).
    id
    OG000
    title
    LY3499446 and Cetuximab Phase 1
population Description
Zero participants were analyzed due to early termination of study.
reporting Status
POSTED
time Frame
Predose Cycle 1 Day 1 through Cycle 3 Day 1 (21 Day Cycles)
title
Phase 1: PK: Average Concentration at Steady State of LY3499446 in Combination With Cetuximab
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice